Clinical Trial Closeup

Edited by Emmett T. Cunningham Jr., MD, PhD

Targeting a key GA factor at its source

Investigational treatment FB-LRX targets complement factor B further up the complement cascade.

Targeting a novel enzyme in GA

An investigative antibody aims to inhibit HtrA1 that contributes to progression of geographic atrophy.

Potential of KSI-301 to extend treatment

The latest results reported efficacy up to five months after the last loading dose.

Modulating macrophages to target GA

Investigational candidate aims to change macrophage behavior in management of dry age-related macular degeneration.

Wet AMD gene therapy shows promise

Phase I/IIa results of RGX-314 confirm protein uptake over months.

What’s Next for Bispecific Antibody Faricimab

With the Phase II BOULEVARD trial completed, this dual-action, single-molecule agent for DME heads into Phase III trials.

A Deeper Dive Into Abicipar Trials

Answers about vision outcomes, inflammation and where it fits in the treatment armamentarium.

A Smaller, Faster Anti-VEGF Therapy

How brolucizumab may extend dosing out to 12 weeks.

Moving the Needle on Ocular Cancer

How AU-011 selectively targets melanoma without damaging nearby ocular tissue.

A Drop for DME and AMD

Are clinical investigators close to finding the Holy Grail for retinal disease?

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.